Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study)

Lung Cancer

Volumn 102, Issue , 2016, Pages 30-37

  Cicènas, Saulius ^a   Geater, Sarayut Lucien ^b   Petrov, Petar ^c   Hotko, Yevgeniy ^d   Hooper, Gregory ^e   Xia, Fan ^f   Mudie, Nadejda ^g   Wu, Yi Long ^h  

^a NATIONAL CANCER INSTITUTE   (Lithuania)

^b PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^c Department of Medical Oncology and Oncology Diseases in Gastroenterology   (Bulgaria)

^d Uzhgorod Central City Hospital   (Ukraine)

^e ROCHE PRODUCTS LTD   (United Kingdom)

^f Roche R D Center (China) Ltd   (China)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

First line erlotinib; Maintenance erlotinib; Non small cell lung cancer; Platinum based chemotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PLACEBO; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NATIONAL HEALTH ORGANIZATION; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; LUNG TUMOR; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS;

EID: 85007613615     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.10.007     Document Type: Article

References (8)

1. [1] Cappuzzo, F., Ciuleanu, T., Stelmakh, L., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre randomised, placebo-controlled phase 3 study. Lancet Oncol. 11 (2010), 521–529.
2. [2] Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur. J. Cancer 45 (2009), 228–247.
3. [3] Pérol, M., Chouaid, C., Pérol, D., et al. Randomized phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 30 (2012), 3516–3524.
4. [4] Yang, J.C., Srimuninnimit, V., Ahn, M.J., et al. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: final overall survival results from a randomized phase 3 study. J. Thorac. Oncol. 50 (2015), 2219–2230.
5. [5] Osarogiagbon, R.U., Cappuzzo, F., Ciuleanu, T., Leon, L., Klughammer, B., Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. Transl. Lung Cancer Res. 4 (2015), 465–474.
6. [6] Zhu, C.Q., da Cunha Santos, G., Ding, K., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR21. J. Clin. Oncol. 26 (2008), 4268–4275.
7. [7] Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T., et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353 (2005), 123–132.
8. [8] Zhou, C., Wu, Y.L., Chen, G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre open-label, randomised, phase 3 study. Lancet Oncol. 12 (2011), 735–742.